Volume 12 Supplement 1

Melanoma Bridge 2013: Poster and Oral Presentations

Open Access

Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials

  • Reinhard Dummer1Email author,
  • Dirk Schadendorf2,
  • Paolo A Ascierto3,
  • James Larkin4,
  • Celeste Lebbé5 and
  • Axel Hauschild6
Journal of Translational Medicine201412(Suppl 1):P8

https://doi.org/10.1186/1479-5876-12-S1-P8

Published: 6 May 2014

Background

Dacarbazine (DTIC) is currently the only agent approved throughout Europe for patients with previously untreated, advanced melanoma that is not restricted by tumour genotype (e.g. BRAF status). Based on recent trials in patients with previously untreated, advanced melanoma, median overall survival (OS) and a 1-year OS rate of approximately 9 months and 36% represent conservative, historical benchmarks for DTIC monotherapy [1–5]. Data from clinical trials and expanded access programmes show that ipilimumab treatment consistently provides a proportion of patients with long-term clinical benefit, irrespective of whether they are pretreated or treatment-naive. In Europe, ipilimumab is indicated for use in adult patients who have received prior therapy. To support the use of ipilimumab in the previously untreated setting, data were analysed from ipilimumab clinical trials.

Materials and methods

Data were pooled from chemotherapy-naive patients who received ipilimumab 3 mg/kg as monotherapy in one of four randomised clinical trials: MDX010-20 (NCT00094653), a phase 3 trial of ipilimumab alone or in combination with gp100 vaccine versus the vaccine alone; MDX010-08 (NCT00050102), a phase 2 multi-dose study of ipilimumab with or without dacarbazine; CA184-004 (NCT00261365), a prospective phase 2 biomarker study, and CA184-022 (NCT00289640), a phase 2, dose-ranging study. Details on these four trials have previously been published [6–9]. Patients received ipilimumab 3 mg/kg x 4 doses with the option for retreatment (MDX010-20) or maintenance therapy (CA184-004/022).

Results

Of the patients who received ipilimumab 3 mg/kg within one of the four clinical trials described above, 78 had not received prior chemotherapy and were eligible for analysis. Of these, 27% had elevated lactate dehydrogenase levels at baseline and 53% had received prior immunotherapy for advanced melanoma. With a median follow-up of 11.6 months (range: 0.03–69.7), median overall survival was 13.47 months (95% confidence intervals [CI]: 11.2–19.6) and the one- and two-year survival rates were 54.1% (95% CI: 42.5–65.6) and 31.6% (95% CI: 20.7–42.9), respectively. Survival outcomes compared favourably to historical observations with dacarbazine in phase 3 trials of patients with previously untreated, advanced melanoma.

Conclusions

Therapeutic options for treatment-naïve patients remain limited. OS data from chemotherapy-naive patients 368/400 words)

Authors’ Affiliations

(1)
University Hospital Zurich
(2)
University Hospital Essen
(3)
Istituto Nazionale Tumori Napoli, Fondazione G
(4)
Department of Medicine, The Royal Marsden Hospital
(5)
Department of Dermatology, APHP St Louis Hospital, University Paris Diderot
(6)
University Hospital Schleswig-Holstein

References

  1. Robert C, Thomas L, Bondarenko I: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011, 364: 2517-2526. 10.1056/NEJMoa1104621.View ArticlePubMedGoogle Scholar
  2. Patel PM, Suciu S, Mortier L: Extended schedule, escalated dose temozolomide versus dacarbazine in Stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer. 2011, 47: 1476-1483. 10.1016/j.ejca.2011.04.030.View ArticlePubMedGoogle Scholar
  3. Middleton MR, Grob JJ, Aaronson N: Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000, 18: 158-166.PubMedGoogle Scholar
  4. Chapman PB, Einhorn LH, Meyers ML: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999, 17: 2745-2751.PubMedGoogle Scholar
  5. Avril MF, Aamdal S, Grob JJ: Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: Phase III study. J Clin Oncol. 2004, 22: 1118-1125. 10.1200/JCO.2004.04.165.View ArticlePubMedGoogle Scholar
  6. Hodi FS, O'Day SJ, McDermott DF: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010, 363: 711-723. 10.1056/NEJMoa1003466.PubMed CentralView ArticlePubMedGoogle Scholar
  7. Hersh EM, O'Day SJ, Powderly J: A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs. 2011, 29: 489-498. 10.1007/s10637-009-9376-8.View ArticlePubMedGoogle Scholar
  8. Wolchok JD, Neyns B, Linette G: Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010, 11: 155-164. 10.1016/S1470-2045(09)70334-1.View ArticlePubMedGoogle Scholar
  9. Hamid O, Schmidt H, Nissan A: A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011, 9: 204-10.1186/1479-5876-9-204.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Dummer et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement